Loading patent…
AssigneesUniversity of Pittsburgh—Of the Commonwealth System of Higher Education, The Trustees of the University of Pennsylvania
InventorsChristopher Donnelly, Jacob Mann, James Shorter, Lin Guo, Bede Portz
Estimating the term…
Disclosed herein are methods to treat a neurodegenerative disease comprising administering to a subject with a neurodegenerative disease a therapeutically effective amount of a polynucleotide that binds a nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide can aggregate in cells and is associated with a neurodegenerative disease. Also disclosed are methods to inhibit protein aggregation in a cell comprising contacting the cell with a composition comprising a polynucleotide that binds a nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide can aggregate in cells and is associated with a neurodegenerative disease. Additionally disclosed are compositions comprising a polynucleotide that binds a nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide can aggregate in cells and is associated with a neurodegenerative disease.
A method to inhibit nucleic acid-binding polypeptide aggregation in a neuronal cell comprising contacting the neuronal cell with a composition comprising a polynucleotide that binds the nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide aggregates in the neuronal cell and is associated with a neurodegenerative disease, wherein the nucleic acid-binding polypeptide is Fused in Sarcoma RNA binding protein (FUS), and wherein the neurodegenerative disease is selected from Multisystem Proteinopathy, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Alzheimer's Disease, Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Cortical Basal Degeneration, and Huntington's Disease, wherein the polynucleotide comprises SEQ ID NO:
A method to inhibit nucleic acid-binding polypeptide aggregation in a neuronal cell comprising contacting the neuronal cell with a composition comprising a polynucleotide that binds the nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide aggregates in the neuronal cell and is associated with a neurodegenerative disease, wherein the nucleic acid-binding polypeptide is FUS, and wherein the neurodegenerative disease is selected from Multisystem Proteinopathy, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Alzheimer's Disease, Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Cortical Basal Degeneration, and Huntington's Disease, wherein the polynucleotide comprises SEQ ID NO:
A method to inhibit nucleic acid-binding polypeptide aggregation in a neuronal cell comprising contacting the neuronal cell with a composition comprising a polynucleotide that binds the nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide aggregates in the neuronal cell and is associated with a neurodegenerative disease, wherein the nucleic acid-binding polypeptide is FUS, and wherein the neurodegenerative disease is selected from Multisystem Proteinopathy, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Alzheimer's Disease, Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Cortical Basal Degeneration, and Huntington's Disease, wherein the polynucleotide comprises SEQ ID NO:
A method to inhibit nucleic acid-binding polypeptide aggregation in a neuronal cell comprising contacting the neuronal cell with a composition comprising a polynucleotide that binds the nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide aggregates in the neuronal cell and is associated with a neurodegenerative disease, wherein the nucleic acid-binding polypeptide is FUS, and wherein the neurodegenerative disease is selected from Multisystem Proteinopathy, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Alzheimer's Disease, Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Cortical Basal Degeneration, and Huntington's Disease, wherein the polynucleotide comprises SEQ ID NO:
A method to inhibit nucleic acid-binding polypeptide aggregation in a neuronal cell comprising contacting the neuronal cell with a composition comprising a polynucleotide that binds the nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide aggregates in the neuronal cell and is associated with a neurodegenerative disease, wherein the nucleic acid-binding polypeptide is FUS, and wherein the neurodegenerative disease is selected from Multisystem Proteinopathy, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Alzheimer's Disease, Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Cortical Basal Degeneration, and Huntington's Disease, wherein the polynucleotide comprises SEQ ID NO:
A method to inhibit nucleic acid-binding polypeptide aggregation in a neuronal cell comprising contacting the neuronal cell with a composition comprising a polynucleotide that binds the nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide aggregates in the neuronal cell and is associated with a neurodegenerative disease, wherein the nucleic acid-binding polypeptide is FUS, and wherein the neurodegenerative disease is selected from Multisystem Proteinopathy, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Alzheimer's Disease, Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Cortical Basal Degeneration, and Huntington's Disease, wherein the polynucleotide comprises SEQ ID NO:
Dependencies are inferred from the claim text.